Department of Cardiothoracic Surgery, New York University Langone Health, New York, NY.
Department of Cardiovascular and Thoracic Surgery, North Shore University Hospital, Northwell Health, Manhasset, NY.
J Thorac Cardiovasc Surg. 2022 Aug;164(2):557-568.e1. doi: 10.1016/j.jtcvs.2021.07.059. Epub 2021 Sep 14.
This pilot study sought to evaluate the feasibility of our donation after circulatory death (DCD) heart transplantation protocol using cardiopulmonary bypass (CPB) for normothermic regional reperfusion (NRP).
Suitable local DCD candidates were transferred to our institution. Life support was withdrawn in the operating room (OR). On declaration of circulatory death, sternotomy was performed, and the aortic arch vessels were ligated. CPB was initiated with left ventricular venting. The heart was reperfused, with correction of any metabolic abnormalities. CPB was weaned, and cardiac function was assessed at 30-minute intervals. If accepted, the heart was procured with cold preservation and transplanted into recipients in a nearby OR.
Between January 2020 and January 2021, a total of 8 DCD heart transplants were performed: 6 isolated hearts, 1 heart-lung, and 1 combined heart and kidney. All donor hearts were successfully resuscitated and weaned from CPB without inotropic support. Average lactate and potassium levels decreased from 9.39 ± 1.47 mmol/L to 7.20 ± 0.13 mmol/L and 7.49 ± 1.32 mmol/L to 4.36 ± 0.67 mmol/L, respectively. Post-transplantation, the heart-lung transplant recipient required venoarterial extracorporeal membrane oxygenation for primary lung graft dysfunction but was decannulated on postoperative day 3 and recovered uneventfully. All other recipients required minimal inotropic support without mechanical circulatory support. Survival was 100% with a median follow-up of 304 days (interquartile range, 105-371 days).
DCD heart transplantation outcomes have been excellent. Our DCD protocol is adoptable for more widespread use and will increase donor heart availability in the United States.
本初步研究旨在评估使用体外循环(CPB)进行常温区域性再灌注(NRP)的我们的心脏死亡后捐献(DCD)心脏移植方案的可行性。
将合适的本地 DCD 候选者转移到我们的机构。在手术室(OR)中撤回生命支持。在宣布循环死亡时,进行胸骨切开术,并结扎主动脉弓血管。用左心室通风开始 CPB。心脏再灌注,纠正任何代谢异常。CPB 逐渐减少,每 30 分钟评估一次心脏功能。如果接受,心脏将进行冷保存并在附近的 OR 中移植给受体。
在 2020 年 1 月至 2021 年 1 月期间,共进行了 8 例 DCD 心脏移植:6 例孤立心脏,1 例心肺,1 例联合心脏和肾脏。所有供体心脏均成功复苏,无需正性肌力支持即可从 CPB 中脱机。平均乳酸和钾水平从 9.39±1.47mmol/L 降至 7.20±0.13mmol/L 和 7.49±1.32mmol/L 降至 4.36±0.67mmol/L。移植后,心肺移植受者因原发性肺移植物功能障碍需要静脉动脉体外膜氧合,但在术后第 3 天拔管并顺利恢复。所有其他受者均需要最小的正性肌力支持,无需机械循环支持。存活率为 100%,中位随访时间为 304 天(四分位距,105-371 天)。
DCD 心脏移植结果非常出色。我们的 DCD 方案可广泛采用,并将增加美国供体心脏的可用性。